Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 9/20 | 0.59 |
| ▸ | JAK1 | P23458 | 4/20 | 0.48 |
| ▸ | JAK3 | P52333 | 4/20 | 0.48 |
| ▸ | TYK2 | P29597 | 3/20 | 0.48 |
| ▸ | BTK | Q06187 | 12/20 | 0.47 |
| ▸ | PARP1 | P09874 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL146349 | 0.78 | JAK2 (0.76) | JAK2TYK2BTK | |
| SCHEMBL178713 | 0.75 | JAK2 (0.78) | JAK2 | |
| SCHEMBL144432 | 0.75 | JAK2 (1.00) | JAK2PARP1 | |
| SCHEMBL27998034 | 0.75 | JAK2 (0.47) | JAK2JAK1JAK3TYK2BTK | |
| SCHEMBL29972939 | 0.74 | POLB (0.49) | JAK2JAK1JAK3 | |
| SCHEMBL146141 | 0.73 | JAK2 (0.51) | JAK2JAK1JAK3TYK2BTK | |
| SCHEMBL147871 | 0.73 | AURKA (0.53) | JAK2JAK1JAK3TYK2PARP1 | |
| SCHEMBL6154534 | 0.73 | ACKR3 (0.48) | JAK2JAK1JAK3PARP1 | |
| SCHEMBL148096 | 0.71 | ULK1 (0.53) | JAK2JAK1JAK3TYK2BTK | |
| SCHEMBL148095 | 0.71 | ULK1 (0.53) | JAK2JAK1JAK3TYK2BTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8084620-B2 | Carbazole carboxamide compounds useful as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-12-27 | — | — | US | disclosed |
| US-20100160303-A1 | CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2010-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160303-A1 | CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS | BTK, FLT3, JAK1 | JAK2 13/4885JAK1 3/4885JAK3 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.